Press Release

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014.

February 14, 2014

Ability Pharmaceuticals, SL announced today that Carles Domènech, PhD, Chief Executive Officer and co-Founder, will be presenting at the 7th Annual European Life Sciences CEO Forum on March 5, 2014 at the Hilton Zurich Airport Hotel, Switzerland. The conference is highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.

Dr. Domènech will present a company overview and will pursuit Ability Pharmaceuticals’s ongoing contacts with the industry and investors.

About Ability Pharmaceuticals
 
Ability Pharmaceuticals is a drug research and development company founded in 2009 with headquarters in Bellaterra (Barcelona, Catalonia, Spain) at Research Park of the Autonomous University of Barcelona. Current investors in the company are the specialized biotech venture capital company Inveready Capital Company, the founders and private investors.
 
Ability Pharmaceuticals develops highly differentiated innovative cancer drugs, with a novel mechanism of action. The company has two drug candidates in development: ABTL0812, which is in clinical development, with phase Ib clinical trials starting in February  2014 in lung cancer and pancreatic cancer starting; and ABTL815, expected to start preclinical development in 1Q 2014.

LATEST NEWS

11.05.2021

Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info
28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG